Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">On The Wires<ul><li>Clearside Biomedical (<strong>CLSD</strong>) announced the enrollment of the first patient in a Phase 3 clinical trial («SAPPHIRE») of Zuprata, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, used together with EYLEA® (aflibercept) for the treatment of macular edema associated with retinal vein occlusion.</li><li>Imprimis Pharmaceuticals (<strong>IMMY</strong>) announced that it has begun shipping its core sterile ophthalmic medications to select customers from its FDA-registered outsourcing facility without the need for a patient-specific prescription. Over the next few weeks Imprimis' flagship Dropless Therapy injectable and LessDrops topical formulations will become available to all customers.</li><li>A new multi-year agreement between Microsoft (<strong>MSFT</strong>) and MGM Resorts International (<strong>MGM</strong>) is a first for both companies. To MGM Resorts, the deal represents the largest single-corporation meeting event ever hosted by the leading global entertainment company. To Microsoft it marks the first time the computer giant has combined four separate annual events, with as many as 30,000 participants, into one signature meeting.</li><li>AdCare Health Systems (<strong>ADK</strong>) announced it has signed a letter of intent to purchase an assisted living facility with 106 operational beds located in Alabama for $5.5 million.</li><li>TRACON Pharmaceuticals (<strong>TCON</strong>) announced that it has initiated patient dosing in its Phase 3 TAPPAS (TRC105 And Pazopanib versus Pazopanib alone in patients with advanced AngioSarcoma) trial of TRC105.</li></ul></td> </tr></table>"